Selective muscarinic M1 antagonists: drug design and discovery
| Autor: | E. S. C. Wu, Dan Widzowski, Herbert F. Helander |
|---|---|
| Rok vydání: | 1997 |
| Předmět: |
Pharmacology
Drug business.industry media_common.quotation_subject Peptic Muscarinic acetylcholine receptor M1 Ipratropium bromide medicine.disease Pirenzepine Obstructive lung disease chemistry.chemical_compound chemistry Telenzepine Drug Discovery Muscarinic acetylcholine receptor medicine business media_common medicine.drug |
| Zdroj: | Drug Discovery Today. 2:341-350 |
| ISSN: | 1359-6446 |
| Popis: | Years of clinical research to treat disorders such as peptic ulcers and obstructive lung disease with the first generation of modestly selective M1 antagonists (e.g. pirenzepine, telenzepine) have been disappointing. For some indications (chronic obstructive pulmonary disease), nonselective antagonists (ipratropium bromide) have exhibited better clinical efficacy. The advent of a new generation of centrally active and highly selective M1 antagonists, such as PD150714, spirotramine FC1594, (-)-S-ET126 and R-4-(pyrrolidino)-1-(4-fluorophenylcarbamoyloxy)-1-phenyl-2-butyne (4-F-PhPyMcN), offers new opportunities for using selective muscarinic agents as therapeutic agents or research tools. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect